IONIS PHARMACEUTICALS INC (IONS)

US4622221004 - Common Stock

36.33  -0.2 (-0.55%)

After market: 36.78 +0.45 (+1.24%)

Fundamental Rating

3

IONS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. The financial health of IONS is average, but there are quite some concerns on its profitability. IONS is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

IONS had negative earnings in the past year.
IONS had a negative operating cash flow in the past year.
IONS had negative earnings in 4 of the past 5 years.
In multiple years IONS reported negative operating cash flow during the last 5 years.

1.2 Ratios

IONS has a better Return On Assets (-11.65%) than 86.30% of its industry peers.
With a decent Return On Equity value of -54.16%, IONS is doing good in the industry, outperforming 64.41% of the companies in the same industry.
Industry RankSector Rank
ROA -11.65%
ROE -54.16%
ROIC N/A
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of IONS (98.70%) is better than 98.04% of its industry peers.
IONS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IONS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%

More info and screens

4

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
IONS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IONS has more shares outstanding
IONS has a better debt/assets ratio than last year.

2.2 Solvency

IONS has an Altman-Z score of 1.26. This is a bad value and indicates that IONS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IONS (1.26) is better than 67.62% of its industry peers.
IONS has a Debt/Equity ratio of 1.86. This is a high value indicating a heavy dependency on external financing.
IONS has a Debt to Equity ratio of 1.86. This is amonst the worse of the industry: IONS underperforms 81.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Altman-Z 1.26
ROIC/WACCN/A
WACC10.02%

2.3 Liquidity

A Current Ratio of 8.91 indicates that IONS has no problem at all paying its short term obligations.
IONS has a Current ratio of 8.91. This is in the better half of the industry: IONS outperforms 76.33% of its industry peers.
IONS has a Quick Ratio of 8.82. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IONS (8.82) is better than 76.51% of its industry peers.
Industry RankSector Rank
Current Ratio 8.91
Quick Ratio 8.82

More info and screens

6

3. Growth

3.1 Past

IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.79%, which is quite impressive.
IONS shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.58%.
The Revenue has been growing slightly by 5.60% on average over the past years.
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.77%
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Sales Q2Q%-6.94%

3.2 Future

The Earnings Per Share is expected to grow by 20.43% on average over the next years. This is a very strong growth
IONS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.32% yearly.
EPS Next Y-36.36%
EPS Next 2Y-20.11%
EPS Next 3Y-3.45%
EPS Next 5Y20.43%
Revenue Next Year-2.16%
Revenue Next 2Y7.57%
Revenue Next 3Y12.98%
Revenue Next 5Y23.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IONS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IONS's earnings are expected to decrease with -3.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.11%
EPS Next 3Y-3.45%

More info and screens

0

5. Dividend

5.1 Amount

IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (12/26/2024, 8:22:11 PM)

After market: 36.78 +0.45 (+1.24%)

36.33

-0.2 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)02-19 2025-02-19/amc
Inst Owners94.22%
Inst Owner Change9.93%
Ins Owners0.73%
Ins Owner Change-0.17%
Market Cap5.74B
Analysts81.29
Price Target62.22 (71.26%)
Short Float %6.77%
Short Ratio7.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.8%
Min EPS beat(2)19.5%
Max EPS beat(2)52.1%
EPS beat(4)4
Avg EPS beat(4)43.28%
Min EPS beat(4)8.61%
Max EPS beat(4)92.92%
EPS beat(8)7
Avg EPS beat(8)21.61%
EPS beat(12)10
Avg EPS beat(12)53.41%
EPS beat(16)12
Avg EPS beat(16)42.04%
Revenue beat(2)2
Avg Revenue beat(2)24.06%
Min Revenue beat(2)0.96%
Max Revenue beat(2)47.15%
Revenue beat(4)3
Avg Revenue beat(4)29.07%
Min Revenue beat(4)-14.17%
Max Revenue beat(4)82.33%
Revenue beat(8)6
Avg Revenue beat(8)18.67%
Revenue beat(12)9
Avg Revenue beat(12)19.1%
Revenue beat(16)10
Avg Revenue beat(16)11.93%
PT rev (1m)-1.18%
PT rev (3m)-1.84%
EPS NQ rev (1m)1.51%
EPS NQ rev (3m)-9.47%
EPS NY rev (1m)2.71%
EPS NY rev (3m)6.06%
Revenue NQ rev (1m)1.06%
Revenue NQ rev (3m)-18.1%
Revenue NY rev (1m)-0.51%
Revenue NY rev (3m)-1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.14
P/FCF N/A
P/OCF N/A
P/B 8.66
P/tB 8.66
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-3.69
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.23
OCFYN/A
SpS5.09
BVpS4.2
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.65%
ROE -54.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.7%
FCFM N/A
ROA(3y)-8%
ROA(5y)-6.8%
ROE(3y)-48.5%
ROE(5y)-37.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 1.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.88%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.91
Quick Ratio 8.82
Altman-Z 1.26
F-Score6
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)115.43%
Cap/Depr(5y)157.47%
Cap/Sales(3y)2.39%
Cap/Sales(5y)2.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.77%
EPS Next Y-36.36%
EPS Next 2Y-20.11%
EPS Next 3Y-3.45%
EPS Next 5Y20.43%
Revenue 1Y (TTM)30.58%
Revenue growth 3Y2.6%
Revenue growth 5Y5.6%
Sales Q2Q%-6.94%
Revenue Next Year-2.16%
Revenue Next 2Y7.57%
Revenue Next 3Y12.98%
Revenue Next 5Y23.32%
EBIT growth 1Y33.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.92%
EBIT Next 3Y0.97%
EBIT Next 5YN/A
FCF growth 1Y-421.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.75%
OCF growth 3YN/A
OCF growth 5YN/A